Pancreatic Cancer Research

ResearcherAsan Medical CenterActive in the last 2 years

Jin‐hong Park

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1088-0174; OpenAlex author ID A5100734350, A5113678181. Sources: OpenAlex.

Their work

Papers
18 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
45
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: 2 papers · 2018: 2 papers · 2019: 2 papers · 2020: 3 papers · 2021: none · 2022: 4 papers · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 18

  1. Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SABER): A Randomized Open-Label Phase 2 Tri… Last author DOI 10.1245/s10434-026-19762-3↗
  2. Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline resectable and locally advanced pancrea… Co-author DOI 10.1016/j.pan.2024.02.004↗
  3. Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX. Co-author DOI 10.4143/crt.2022.409↗
  4. Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1177/17588359221097190↗
  5. Current status and future perspective of neoadjuvant therapy in locally advanced and borderline resectable pancreatic adenocarcinoma: a narrative review. Co-author DOI 10.21037/cco-21-166↗
  6. Stereotactic Body Radiation Therapy versus Concurrent Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis. Co-author DOI 10.3390/cancers14051166↗
  7. Stereotactic body radiation therapy for pancreatic cancer: a potential ally in the era of immunotherapy? Co-author DOI 10.3857/roj.2022.00479↗
  8. Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biom… Co-author DOI 10.1038/s41416-020-0867-x↗
  9. FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. Co-author DOI 10.1177/1758835920953294↗
  10. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.4143/crt.2019.190↗
  11. Stereotactic body radiation therapy for locally advanced pancreatic cancer. Co-author DOI 10.1371/journal.pone.0214970↗
  12. Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Canc… Co-author DOI 10.3390/cancers11030278↗
  13. Dosimetric analysis of stereotactic rotational versus static intensity-modulated radiation therapy for pancreatic cancer. First author DOI 10.1016/j.canrad.2018.01.007↗
  14. Prognosis of Pancreatic Cancer Patients with Synchronous or Metachronous Malignancies from Other Organs Is Better than Those with Pancreatic Cancer Only. Co-author DOI 10.4143/crt.2017.494↗
  15. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen. Co-author DOI 10.18632/oncotarget.17940↗
  16. Postoperative Radiotherapy for Pancreatic Cancer with Microscopically-positive Resection Margin. Co-author DOI 10.21873/anticanres.11374↗
  17. Survival effect of tumor size and extrapancreatic extension in surgically resected pancreatic cancer: proposal for improved T classification. Co-author DOI 10.1016/j.humpath.2014.06.030↗
  18. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally a… Co-author DOI 10.1016/j.surg.2012.03.010↗

Closest collaborators

The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kyu‐pyo Kim · 14 shared papers, 2014–2026 · strength 1.54
  2. Changhoon Yoo · 13 shared papers, 2017–2026 · strength 1.52
  3. Dae Wook Hwang · 12 shared papers, 2017–2026 · strength 1.36
  4. Sang Soo Lee · 14 shared papers, 2012–2024 · strength 1.34
  5. Baek‐Yeol Ryoo · 12 shared papers, 2017–2026 · strength 1.32
  6. Tae Jun Song · 11 shared papers, 2017–2026 · strength 1.27
  7. Song Cheol Kim · 13 shared papers, 2012–2026 · strength 1.24
  8. Ki Byung Song · 11 shared papers, 2014–2026 · strength 1.14
  9. Do Hyun Park · 10 shared papers, 2012–2024 · strength 0.97
  10. Dongwook Oh · 6 shared papers, 2020–2026 · strength 0.89
  11. Dong Wan Seo · 8 shared papers, 2012–2024 · strength 0.75
  12. Woohyung Lee · 5 shared papers, 2020–2026 · strength 0.68
  13. Myung‐Hwan Kim · 7 shared papers, 2012–2022 · strength 0.54
  14. Bong Jun Kwak · 3 shared papers, 2022–2024 · strength 0.42
  15. Hyehyun Jeong · 2 shared papers, 2024–2026 · strength 0.41
  16. Inkeun Park · 2 shared papers, 2024–2026 · strength 0.41
  17. Seung Soo Lee · 2 shared papers, 2020–2026 · strength 0.33
  18. Seung‐Mo Hong · 4 shared papers, 2014–2024 · strength 0.33
  19. Dong‐Wan Seo · 4 shared papers, 2014–2022 · strength 0.31
  20. Yejong Park · 2 shared papers, 2023–2024 · strength 0.30
  21. Jong Hoon Kim · 4 shared papers, 2012–2022 · strength 0.28
  22. Jaewon Hyung · 2 shared papers, 2020–2022 · strength 0.27
  23. So Heun Lee · 2 shared papers, 2022–2023 · strength 0.26
  24. Jinhong Jung · 2 shared papers, 2019–2022 · strength 0.20
  25. Inhwan Hwang · 2 shared papers, 2020 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.